Exploring how playing in sand affects atopic dermatitis in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of exposure to microbial diversity through sand play on children with atopic dermatitis. It aims to determine if playing in a sandbox can reduce eczema symptoms and alter immune responses by assessing various health indicators. Approximately 80 children aged 2-5 with atopic dermatitis will be recruited to participate in this interventional study, where they will be divided into groups receiving either a microbial intervention or a placebo. The study will measure changes in eczema severity, immune markers, and microbial communities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eczema Area and Severity Index ≥ 2

Exclusion Criteria:

* Eczema Area and Severity Index \< 2
* Immune deficiencies, i.e., antibody deficiency
* Immunosuppressive systematic medications
* A disease affecting immune response (e.g., colitis ulcerosa, rheumatoid arthritis, Crohn's disease, diabetes)
* Cancer diagnosis
* Topical medication for the treatment of atopic dermatitis during the trial
* Disability affecting the immune response (e.g. Down's syndrome)
* Non-participation in the national vaccine program
* Participation in another intervention or follow-up study

Where it's running

• Natural Resources Institute Finland
  Helsinki, Uusimaa, Finland Recruiting
• Tampere University
  Tampere, Finland Recruiting

Study contacts

• Principal investigator: Aki Sinkkonen — Natural Resources Institute Finland
• Study coordinator: Sanna Hurtola
• Email: sanna.hurtola@luke.fi
• Phone: +358295322500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Research on improving kindergarten yards for children's health

  This study is testing whether making kindergarten yards more natural and full of plants can improve the health and learning of children aged 1-5 by looking at things like allergies, asthma, and their overall well-being.

  Recruiting at 2 sites Natural Resources Institute Finland · Helsinki, Uusimaa and 1 other locations · NCT06390878

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.